Abstract
Radiation-induced lung fibrosis (RILF) is a severe side effect of radiotherapy in lung cancer patients that presents as a progressive pulmonary injury combined with chronic inflammation and exaggerated organ repair. RILF is a major barrier to improving the cure rate and well-being of lung cancer patients because it limits the radiation dose that is required to effectively kill tumor cells and diminishes normal lung function. Although the exact mechanism is unclear, accumulating evidence suggests that various cells, cytokines and regulatory molecules are involved in the tissue reorganization and immune response modulation that occur in RILF. In this review, we will summarize the general symptoms, diagnostics, and current understanding of the cells and molecular factors that are linked to the signaling networks implicated in RILF. Potential approaches for the treatment of RILF will also be discussed. Elucidating the key molecular mediators that initiate and control the extent of RILF in response to therapeutic radiation may reveal additional targets for RILF treatment to significantly improve the efficacy of radiotherapy for lung cancer patients.
Keywords: Fibrosis, lung cancer, radiotherapy, side effects.
Current Drug Targets
Title:Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Volume: 14 Issue: 11
Author(s): Nian-Hua Ding, Jian Jian Li and Lun-Quan Sun
Affiliation:
Keywords: Fibrosis, lung cancer, radiotherapy, side effects.
Abstract: Radiation-induced lung fibrosis (RILF) is a severe side effect of radiotherapy in lung cancer patients that presents as a progressive pulmonary injury combined with chronic inflammation and exaggerated organ repair. RILF is a major barrier to improving the cure rate and well-being of lung cancer patients because it limits the radiation dose that is required to effectively kill tumor cells and diminishes normal lung function. Although the exact mechanism is unclear, accumulating evidence suggests that various cells, cytokines and regulatory molecules are involved in the tissue reorganization and immune response modulation that occur in RILF. In this review, we will summarize the general symptoms, diagnostics, and current understanding of the cells and molecular factors that are linked to the signaling networks implicated in RILF. Potential approaches for the treatment of RILF will also be discussed. Elucidating the key molecular mediators that initiate and control the extent of RILF in response to therapeutic radiation may reveal additional targets for RILF treatment to significantly improve the efficacy of radiotherapy for lung cancer patients.
Export Options
About this article
Cite this article as:
Ding Nian-Hua, Li Jian Jian and Sun Lun-Quan, Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/13894501113149990198
DOI https://dx.doi.org/10.2174/13894501113149990198 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Psoriasin, A Multifunctional Player in Different Diseases
Current Protein & Peptide Science Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-analysis
Current Respiratory Medicine Reviews The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
Current Drug Targets Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds
Current Cancer Drug Targets Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane
Current Drug Targets Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences The Integrative Network of Gene Expression, MicroRNA, Methylation and Copy Number Variation in Colon and Rectal Cancer
Current Bioinformatics MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Parathyroid Hormone-Related Protein (PTHrP) in the Pathophysiology of Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer
Current Drug Targets Morpholine Based Diazenyl Chalcones: Synthesis, Antimicrobial Screening and Cytotoxicity Study
Anti-Cancer Agents in Medicinal Chemistry Pemetrexed: Potential Role in the Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
Current Drug Targets Antineoplastic Activities, Apoptotic Mechanism of Action and Structural Properties of a Novel Silver(I) Chelate
Current Medicinal Chemistry